This trial is testing inotuzumab ozogamicin to see if it can help patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment.
1 Primary · 11 Secondary · Reporting Duration: Up to 5 years
Experimental Treatment
80 Total Participants · 2 Treatment Groups
Primary Treatment: Inotuzumab Ozogamicin · No Placebo Group · Phase 2
Age 1 - 21 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: